VerdeMed, a Latin American cannabis company, is sponsoring the 3rd Annual Cannabis Private Investment Summit in Toronto
|
TORONTO, /PRNewswire/ - VERDEMED HOLDINGS INC. ("VerdeMed" or the "Company") proudly announces its sponsorship of the 3rd Annual Kahner Global Cannabis Private Investment Summit, on October 23, 2018, at the offices of Bennett Jones in First Canadian Place. The Summit will explore the opportunities and risks of investing in the cannabis industry. The event is the leading cannabis investing educational summit offered exclusively to high net worth investors and family offices. José Bacellar, President & CEO of VerdeMed, will participate in a panel discussion, Where is Medical Marijuana Going? Latin America: The Next Frontier, together with Benjamin Caplan, MD (founder of CED Clinic) and moderator Kevin McGovern (Chairman & CEO, McGovern Capital and The Water Initiative). For more information, please visit www.verdemed.com José Bacellar President & CEO About VerdeMed VerdeMed is a Canadian pharmaceutical cannabis company with the mission of improving the health of millions of patients in Latin America. VerdeMed brings a unique combination of Canadian cannabis industry expertise, Latin American smart capital, international pharmaceutical business knowledge, superior regulatory affairs capabilities, and top-tier medical insight. Based in Toronto, VerdeMed's multi-level and multi-market approach aims to bridge the gap between the pharmaceutical cannabis landscape in Europe and North America and unmet clinical needs in Latin America. The Company's international footprint provides strategic access to market innovations, as well as well-known proven cannabis therapies. Over the next few years, VerdeMed plans to introduce to the Latin American market a range of cannabinoid-based medications that are expected to be approved by the principal regulatory agencies in the region, including ANMAT, Anvisa, COFEPRIS, DIGEMID, Invima, and ISP. VerdeMed is uniquely positioned to help producers and distributors address the high regulatory hurdles in Latin America for Canadian products. The Company is aiming to become the platform of choice for global innovators entering markets in Latin America with new medical cannabis products. VerdeMed has offices in Brazil, Chile, Colombia, and Canada. The Company intends to build management teams and recruit pharmaceutical regulatory affairs partners in Argentina, Mexico, and Peru by the end of 2018, as part of its strategic plan to create a unified business footprint within the principal legal markets in Latin America for medical cannabis and cannabinoid-based pharmaceuticals. José Bacellar José Bacellar is uniquely qualified to lead efforts across multiple jurisdictions, having assisted a number of companies in North America to expand into Latin America. He brings extensive professional experience in the pharmaceutical industry, and he has relevant experience in the medical cannabis industry. Prior positions he has held include Head of Business Development, Canopy Latam; interim COO, Canopy Health (UK); Head of Business Development, ACIC Pharmaceuticals (Canada); CEO, Vetnil (Brazil); and CEO & President, Bombril S/A (Brazil). José Bacellar holds a B.Sc. in Economics and an M.Sc. in Business Administration from the Universidade de Sao Paulo (FEA/USP), and has received an Award of Business Leadership from the Rotman School of Management - University of Toronto. Mr. Bacellar is also a strategy consultant alumnus of McKinsey & Company.
SOURCE Verdemed Holdings Inc. |
View original content: